Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

188.06 -2.50 (-1.31%)

Streaming Delayed Price Updated: 11:30 AM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

59 60 Next >

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock ↗

December 28, 2022

Investors are closely watching two key spaces that could spark Lilly stock.

Via Investor's Business Daily

The Top Three Stocks Analysts Say To Buy

December 28, 2022

The analysts are rewarding companies that prove they can succeed in the face of headwinds and the most upgraded in Q4 2022 are Netflix, Biogen and Nike.

Via MarketBeat

Is Biogen's Stock Too Risky to Invest in? ↗

December 28, 2022

Even at a discount, investors may be taking on a big risk with Biogen.

Via The Motley Fool

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Roche's Follicular Lymphoma Therapy Scores FDA Approval ↗

December 23, 2022

Via Benzinga

1 Green Flag and 1 Red Flag for Biogen ↗

December 23, 2022

Biogen beat the bear market this year.

Via The Motley Fool

Is Biogen Stock a Buy Now? ↗

December 04, 2022

Its revenue now has a plausible path to doubling, but risks remain high.

Via The Motley Fool

CrowdStrike (CRWD) Stock Sinks on Weak Guidance ↗

November 30, 2022

CrowdStrike (CRWD) stock is falling on Wednesday following the release of its earnings report for the third quarter of 2022.

Via InvestorPlace

3 Nasdaq Stocks That Are Up 25% in 3 Months ↗

December 23, 2022

Should you jump on the bandwagon and buy these surging stocks?

Via The Motley Fool

Biogen's Alzheimer's Antibody Might Have A Third Death Associated With ↗

December 22, 2022

A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab.

Via Benzinga

Has This Top Pharma Company Found Its Next Billion-Dollar Product? ↗

December 22, 2022

Eli LIlly is looking to make waves in an important therapeutic area.

Via The Motley Fool

Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease ↗

December 21, 2022

The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for...

Via Talk Markets

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

December 19, 2022

From Biogen Inc.

Via GlobeNewswire

26 Analysts Have This to Say About Biogen ↗

November 30, 2022

Via Benzinga

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond ↗

December 18, 2022

These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.

Via InvestorPlace

Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move ↗

December 18, 2022

These stocks have climbed by double digits this year.

Via The Motley Fool

Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock ↗

December 18, 2022

Both stocks are heading for double-digit gains this year.

Via The Motley Fool

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

December 09, 2022

From Biogen Inc.

Via GlobeNewswire

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

December 08, 2022

The three companies are changing the pharmaceutical industry.

Via The Motley Fool

Why 2023 Could Be a Big Year for Biogen ↗

December 07, 2022

Investors will soon learn if the company's Alzheimer's treatment gets the green light.

Via The Motley Fool

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

December 06, 2022

From Sage Therapeutics, Inc.

Via Business Wire

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

December 05, 2022

From Biogen Inc.

Via GlobeNewswire

Even After This Year’s Melt-Up, Runway Remains for LLY Stock ↗

December 05, 2022

The market hasn't overreacted with its enthusiasm for LLY stock, as the pharma giant makes progress with a blockbuster drug in the making.

Via InvestorPlace

Can These 2 Stocks Crush the Market Again in 2023? ↗

December 04, 2022

Both are riding the wave of major clinical wins

Via The Motley Fool

Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗

December 02, 2022

The S&P 500 is fighting for its 200-day, a critical level for the uptrend.

Via Investor's Business Daily

Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate ↗

November 30, 2022

Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).

Via Benzinga

BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen ↗

November 30, 2022

Biogen (BIIB) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate.

Via InvestorPlace

Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's ↗

November 30, 2022

Via Benzinga

Biogen Stock Is Surging Today: What's Going On? ↗

November 30, 2022

Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's

Via Benzinga

Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday ↗

November 30, 2022

Mizuho cut Alphabet Inc. (NASDAQ: GOOGL) price target from $140 to $135. Mizuho analyst James Lee maintained a Buy rating on the stock. Alphabet shares gained 0.4% to $95.53 in pre-market trading.

Via Benzinga

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.